A PYMNTS Company

Antitrust Chronicle® – Patents, Drugs & Antitrust

Spring 2014, Volume 4, Number 2

Dear Readers, This issue looks at four health issues recently argued by the FTC. First, we deal with the FDA’s REMS (risk evaluation and mitigation strategies) program and how it seems to conflict with the FTC’s desire to encourage generic competition. The FTC is examining branded pharmaceutical firms’ refusal to sell samples of restricted distribution […]

Read More

In case you missed it...



March

This Chronicle brings together contributions that explore the evolving relationship between industrial policy, competition, regulation & technological change from complementary angles.




February

This month’s TechREG Chronicle focuses on online consumer protection, at a moment when regulators on both sides of the Atlantic are reassessing how legacy consumer-protection frameworks apply in digital, data-driven markets.




January

Tech banking charters have returned to the center of regulatory and strategic debate, driven by the convergence of digital assets, stablecoins, and the maturation of fintech business models.


See more Chronicles by year: